Compare ALSN & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | KRYS |
|---|---|---|
| Founded | 1915 | 2015 |
| Country | United States | United States |
| Employees | 4000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.6B |
| IPO Year | 2011 | 2017 |
| Metric | ALSN | KRYS |
|---|---|---|
| Price | $126.62 | $328.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $117.57 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 837.0K | 597.5K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | 3.49 | ★ 3.62 |
| Revenue | ★ $3,010,000,000.00 | $389,130,000.00 |
| Revenue This Year | $94.98 | $38.74 |
| Revenue Next Year | $5.30 | $32.53 |
| P/E Ratio | ★ $35.51 | $90.96 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $76.01 | $142.51 |
| 52 Week High | $137.62 | $382.54 |
| Indicator | ALSN | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 46.41 |
| Support Level | $110.38 | $246.17 |
| Resistance Level | $126.11 | $377.89 |
| Average True Range (ATR) | 4.34 | 14.85 |
| MACD | 0.73 | -2.22 |
| Stochastic Oscillator | 97.33 | 47.90 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.